Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

1ST Biotherapeutics, Inc.

http://www.1stbio.com/

Latest From 1ST Biotherapeutics, Inc.

Finance Watch: Have Biopharma IPOs Hit Their Limit?

Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.

Financing Business Strategies

Finance Watch: Notable Neuroscience VC Deals Include Nura Bio’s $73m Launch

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.

Financing Neurology

Emergings in Brief (7/06)

Start-Up showcases these recently launched companies: Nitric BioTherapeutics, Onset Therapeutics, SpeciGen and VEXIM.

Recent Tech Transfer Deals (7/06)

Each month, Start-Up presents a survey of technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

See All

Company Information

  • Industry
  • Biotechnology
  • Other Names / Subsidiaries
    • 1STBio
    • 1ST Biotherapeutics
UsernamePublicRestriction

Register